Feb 24 2010
TSO3 Inc. ("TSO3") (TSX: TOS) is pleased to announce that it has filed a final short form prospectus with the securities regulatory authorities in all provinces of Canada with respect to a previously announced public offering of 10,000,000 common shares (the "Common Shares") for gross proceeds to the Company of C$16 million. The prospectus also qualifies for the distribution of 150,000 Common shares sold by Simon Robitaille, one of the Company's founders and Chief Scientific Officer, for gross proceeds of $240,000. The offering is being made through a syndicate of underwriters led by Canaccord Adams and including Versant Partners. Closing of the offering is expected to occur on or about March 2, 2010.
The Company has granted the Underwriters an over-allotment option, exercisable for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the number of common shares issued from Treasury pursuant to the Offering, at the offering price of $1.60.
The proceeds from the Offering will be used to support the global commercialization efforts for the STERIZONE(R) 125L+ Sterilizer through its global channel partner, 3M. Additionally, the Company will use a portion of the net proceeds to fund new product initiatives and for working capital purposes.
Source:
TSO3 INC.